[{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Immune globulin human-klhw","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Grifols"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx SE","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Argenx SE"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Novartis"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"Soleo Health \/ GC Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Soleo Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.

                          Brand Name : Alyglo

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 16, 2024

                          Lead Product(s) : Immune Globulin Intravenous, Human

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : GC Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).

                          Brand Name : Leqvio

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : Inclisiran

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Specialty pharmacy partners to dispense nationwide RADICAVA ORS® (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA), which commercializes approved pharmaceutical products in North America.

                          Brand Name : Radicava ORS

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 07, 2022

                          Lead Product(s) : Edaravone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Mitsubishi Tanabe Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Soleo Health offers differentiated capabilities through its ability to collect real-world data and generate intelligent outcomes from VYVGART patients with its exclusive and proprietary clinical outcomes program, SoleMetrics®.

                          Brand Name : Vyvgart

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 24, 2022

                          Lead Product(s) : Efgartigimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Argenx

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Soleo Health was chosen as a limited distributor of XEMBIFY. This is Grifols’ first 20% immune globulin.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 01, 2020

                          Lead Product(s) : Immune globulin human-klhw

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Grifols International

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank